Your email has been successfully added to our mailing list.

×
0 0 0 0.00112233445566777 0.00224466891133553 0.00112233445566777 -0.00448933782267106 -0.0151515151515151
Stock impact report

Morphosys says Novartis takeover progressing as planned for H1 2024 [Reuters]

MorphoSys AG - American Depositary Shares (MOR) 
Company Research Source: Reuters
of this year, in a statement responding to a possible safety risk reported by specialist news website STAT News that knocked the company's share price on Monday. "The planned acquisition by Novartis is progressing steadily," a Morphosys spokesperson said in an emailed response to Reuters. "We remain confident in the benefit-risk profile of the combination of pelabresib and ruxolitinib." Coming soon: Get the latest news and expert analysis about the state of the global economy with Reuters Econ World. Sign up Reporting by Patricia Weiss, Writing by Rachel More, Editing by Andrey Sychev Our Standards: Show less Read more
Impact Snapshot
Event Time:
MOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for MOR alerts
Opt-in for
MOR alerts

from News Quantified
Opt-in for
MOR alerts

from News Quantified